Lung Cancer Awareness Month

Research lab behrakis elliniki simaia

 

Cancer is a generic term for a group of diseases which can affect any body organ or system characterized by rapid, uncontrollable and abnormal cell growth and division, as well as the ability to spread throughout the body (metastasis). The cancer is usually named after the organ where it started from, for example lung cancer whereas metastasis from another organ to the lungs is not lung cancer, but cancer of the organ of origin that has spread to the lungs.

 

Lung cancer is the most common cause of death from cancers in Greece1

 

Causes of Lung Cancer

 

Tobacco smoke through both active and passive smoking is responsible for more than 80% of all lung cancer cases indicating it is a highly preventable disease. A much smaller percentage of cases are attributed to occupational and environmental exposures to known carcinogenic factors such as asbestos, radiation, radon, beryllium, chromium, diesel exhaust and arsenic. 2

 

Symptoms

 

An important characteristic of lung cancer is that it develops slowly over time usually taking up to two decades for signs and symptoms to appear (time-lag effect).

 

In reality, the negative health effects begin from the first cigarette and cumulatively add-up over time (dose and duration-dependent). That’s why physicians ask about the number of cigarettes smoked per day and years of smoking so they can calculate number of pack-years (PY).

 

  • PY= number of packages smoked per day multiplied by years of smoking

Symptoms of lung cancer are relatively vague and vary by each person. Many times symptoms do not present until the cancer has spread to the rest of the body. Some of the symptoms can include:3

 

  • Coughing that progressively worsens and persists
  • Chest pain
  • Shortness of Breath
  • Wheezing
  • Coughing up blood
  • Feeling tired
  • Excessive unexplained weight loss
  • Clubbing of fingernails (when the tip of the finger is enlarged and appears like the round part of an upside-down spoon)

 

Diagnosis and Treatment4

 

Lung cancer has several histological types. Prognosis is different for each case depending on several factors, most importantly, the histological type and disease stage at the time of diagnosis. In clinical practice the main lung cancer differentiations are small cell and non-small cell lung cancer, requiring different therapeutic approaches.

 

Treatment options include surgery, chemotherapy and radiotherapy. Recent advances in chemotherapy (immunotherapy, molecular, targeted or precision therapy), in surgery (minimal invasion and video-assisted procedures) and in diagnosing and staging (CT scan, PET scan, endoscopic ultrasound) have led to early diagnosis, improved prognosis and quality of life.

 

Prevention

 

Lung cancer caused by tobacco smoke is completely preventable through tobacco smoking prevention and cessation. There is no safe limit for smoking or passive smoking. It is highly recommended to avoid smoking and second-hand smoke in order to prevent ever occurrence of lung cancer.

 

Smokers are considered a population at high risk for developing lung cancer. Therefore, the American College of Chest Physicians (ACCP), in their 2021 updated guidelines5, strongly recommend an annual screening with low dose chest CT scan for asymptomatic smokers and former smokers aged 55 to 77 who have smoked 30 pack years or more and either continue to smoke or have quit within the past 15 years.

 

What’s Happening in Greece?

 

Lung cancer is the 3rd overall cause of death in Greece. Additionally, tobacco use is the risk factor responsible for the highest mortality and disability in Greece6.

 

Lung cancer is the most common cancer incidence in Greece, accounting for 13.9% of new cancer cases in Greece in 20207.

 

Lung cancer represents the most common cancer incidence in males (18.7% of new cancer cases in 2020), and the 3rd most common cancer incidence in females (7.7%), following breast (27.5%) and colorectum (11.9%) . However, lung cancer incidence in women is expected to increase in the future due to increased smoking prevalence among women in recent years8.

 

 

The Good News:

 

Smoking and Passive smoking are decreasing in Greece!

 

Smoking prevalence has been steadily declining in Greece since 2012, in particular in a nationwide survey conducted in 2012 smoking prevalence was 37%, whereas in a study conducted in 2020 smoking prevalence was 28%, showing a 24% reduction8! This reduction supports the expectation of a future reduction in lung cancer cases .

 

Since summer 2019, the new smoking ban law has been widely accepted by the Greek public. The law-abiding behavior has led to a dramatic decline in the exposure of non-smokers to second hand smoke a documented cause for lung cancer as well.

 


References

  1. OECD/European Observatory on Health Systems and Policies (2019). Greece: Country Health Profile 2019, State of Health in the EU. https://www.oecd.org/greece/greece-country-health-profile-2019-d87da56a-en.htm
  2. European Lung Foundation. Lung cancer. http://www.europeanlung.org/en/lung-disease-and-information/lung-diseases/lung-cancer.
  3. US. Center of Disease Control and Prevention. CDC – What Are the Symptoms of Lung Cancer? https://www.cdc.gov/cancer/lung/basic_info/symptoms.htm. Published 2013.
  4. National Cancer Institute. Treatment for Cancer – National Cancer Institute. https://www.cancer.gov/about-cancer/treatment. Published 2015.
  5. Mazzone PJ, GA Silvestri, LH Souter, TJ Caverly, JP Kanne, HA Katki, RS Wiener, and FC Detterbeck. 2021. “Screening for Lung Cancer: CHEST Guideline and Expert Panel Report”. Chest.
  6.  Institute for Health Metrics and Evaluation. University of Michigan. Greece profile 2019. http://www.healthdata.org/greece
  7. The Global Cancer Observatory. World Health Organization. Greece. Source Globocan 2020. https://gco.iarc.fr/today/data/factsheets/populations/300-greece-fact-sheets.pdf
  8. Tzortzi A., Kapetanstrataki M., Evangelopoulou V., Behrakis P. 2020. “Smoking in Greece Where we stand in 2020”. Pneumon. 33 (2): 59-67.

 

By Anna Tzortzi, MD, Pulmonologist

Scientific Director “George D. Behrakis Research Lab”

Associate Director “Institute of Public Health, The American College of Greece”

 

and Melpo Kapetanstrataki, Biostatistics Consultant & Technical Support